Literature DB >> 24876087

Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors.

Pierre Seners1, Guillaume Turc1, Marie Tisserand1, Laurence Legrand1, Marc-Antoine Labeyrie1, David Calvet1, Jean-François Meder1, Jean-Louis Mas1, Catherine Oppenheim1, Jean-Claude Baron2.   

Abstract

BACKGROUND AND
PURPOSE: Early neurological deterioration (END) after anterior circulation stroke is a serious clinical event strongly associated with poor outcome. Regarding specifically END occurring within 24 hours of intravenous recombinant tissue-type plasminogen activator, apart from definite causes such as symptomatic intracranial hemorrhage and malignant edema whose incidence, predictors, and clinical management are well established, little is known about END without clear mechanism (ENDunexplained).
METHODS: We analyzed 309 consecutive patients thrombolysed intravenously ≤4.5 hours from onset of anterior circulation stroke. ENDunexplained was defined as a ≥4-point deterioration on 24-hour National Institutes of Health Stroke Scale, without definite mechanism on concomitant imaging. ENDunexplained and no-END patients were compared for pretreatment clinical and imaging (including magnetic resonance diffusion and diffusion/perfusion mismatch volumes) data and 24-hour post-treatment clinical (including blood pressure and glycemic changes) and imaging (24-hour recanalization) data, using univariate logistic regression. Exploratory multivariate analysis was also performed after variable reduction, with bootstrap analysis for internal validation.
RESULTS: Among 33 END patients, 23 (7% of whole sample) had ENDunexplained. ENDunexplained was associated with poor 3-month outcome (P<0.01). In univariate analysis, admission predictors of ENDunexplained included no prior use of antiplatelets (P=0.02), lower National Institutes of Health Stroke Scale score (P<0.01), higher glycemia (P=0.03), larger mismatch volume (P=0.03), and proximal occlusion (P=0.01), with consistent results from the multivariate analysis. Among factors recorded during the first 24 hours, only no recanalization was associated with ENDunexplained in multivariate analysis (P=0.02).
CONCLUSIONS: ENDunexplained affected 7% of patients and accounted for most cases of END. Several predictors and associated factors were identified, with important implications regarding underlying mechanisms and potential prevention of this ominous event.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  stroke; thrombolytic therapy

Mesh:

Substances:

Year:  2014        PMID: 24876087     DOI: 10.1161/STROKEAHA.114.005426

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  29 in total

1.  Revisiting 'progressive stroke': incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke.

Authors:  Pierre Seners; Jean-Claude Baron
Journal:  J Neurol       Date:  2017-04-28       Impact factor: 4.849

2.  Perfusion Changes of Unexplained Early Neurological Deterioration After Reperfusion Therapy.

Authors:  Jingjing Fu; Ying Zhou; Qingqing Li; Genlong Zhong; Sheng Zhang; Ruiting Zhang; Chang Liu; Minming Zhang; Min Lou
Journal:  Transl Stroke Res       Date:  2019-08-28       Impact factor: 6.829

Review 3.  Review of studies on dynamic cerebral autoregulation in the acute phase of stroke and the relationship with clinical outcome.

Authors:  Ricardo C Nogueira; Marcel Aries; Jatinder S Minhas; Nils H Petersen; Li Xiong; Jana M Kainerstorfer; Pedro Castro
Journal:  J Cereb Blood Flow Metab       Date:  2021-09-13       Impact factor: 6.960

4.  Endovascular treatment of ischemic stroke due to isolated internal carotid artery occlusion: ETIS registry data analysis.

Authors:  Adrien Ter Schiphorst; Roxane Peres; Cyril Dargazanli; Raphaël Blanc; Benjamin Gory; Sébastien Richard; Gaultier Marnat; Igor Sibon; Benoit Guillon; Romain Bourcier; Christian Denier; Laurent Spelle; Julien Labreuche; Arturo Consoli; Bertrand Lapergue; Vincent Costalat; Michael Obadia; Caroline Arquizan
Journal:  J Neurol       Date:  2022-03-31       Impact factor: 6.682

5.  Harnessing neurogenesis in the adult brain-A role in type 2 diabetes mellitus and Alzheimer's disease.

Authors:  Orly Lazarov; Richard D Minshall; Marcelo G Bonini
Journal:  Int Rev Neurobiol       Date:  2020       Impact factor: 3.230

6.  Early neurological stability predicts adverse outcome after acute ischemic stroke.

Authors:  Hannah J Irvine; Thomas Wk Battey; Ann-Christin Ostwaldt; Bruce Cv Campbell; Stephen M Davis; Geoffrey A Donnan; Kevin N Sheth; W Taylor Kimberly
Journal:  Int J Stroke       Date:  2016-07-09       Impact factor: 5.266

Review 7.  Utility of perfusion imaging in acute stroke treatment: a systematic review and meta-analysis.

Authors:  Won Hyung A Ryu; Michael B Avery; Navjit Dharampal; Isabel E Allen; Steven W Hetts
Journal:  J Neurointerv Surg       Date:  2016-11-09       Impact factor: 5.836

8.  Symptomatic isolated internal carotid artery occlusion with initial medical management: a monocentric cohort.

Authors:  Adrien Ter Schiphorst; Nicolas Gaillard; Cyril Dargazanli; Isabelle Mourand; Lucas Corti; Mahmoud Charif; Xavier Ayrignac; Anaïs Lippi; Stéphane Bouly; Lalu Thibault; Denis Sablot; Genevieve Blanchet-Fourcade; Nicolas Landragin; Vincent Costalat; Claire Duflos; Caroline Arquizan
Journal:  J Neurol       Date:  2020-08-18       Impact factor: 4.849

9.  Baseline collateral status and infarct topography in post-ischaemic perilesional hyperperfusion: An arterial spin labelling study.

Authors:  Sonu Bhaskar; Andrew Bivard; Peter Stanwell; Mark Parsons; John R Attia; Michael Nilsson; Christopher Levi
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-21       Impact factor: 6.200

10.  Minor stroke due to large artery occlusion. When is intravenous thrombolysis not enough? Results from the SITS International Stroke Thrombolysis Register.

Authors:  Michael V Mazya; Charith Cooray; Kennedy R Lees; Danilo Toni; Gary A Ford; Michal Bar; Senta Frol; Tiago Moreira; Lakshmanan Sekaran; Viktor Švigelj; Nils Wahlgren; Niaz Ahmed
Journal:  Eur Stroke J       Date:  2017-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.